Established antiresorptive treatments for osteoporosis only slow down bone loss, and available osteoanabolic therapies — although more effective — have broad limitations. Recent insights into sex-specific systemic regulation of skeletal mass, an enhanced understanding of the cellular complexity of bone marrow and innovative options such as senolytics have fuelled the development of potentially transformative bone anabolic treatments.
Key advances
-
The newly identified osteoanabolic maternal brain hormone CCN3 has broad implications for the treatment of bone loss-related diseases and enhancement of fracture regeneration4.
-
Schnurri 3 is a new targetable WNT inhibitor for treatment of osteogenesis imperfecta and a potential therapeutic target in other bone conditions5.
-
Spatial mapping of the human bone marrow environment in health and disease on the single-cell level provides a platform to identify new cellular interactions and molecular players relevant to osteoporosis7.
-
A randomized controlled trial exploring the benefits of senolytic treatment on bone parameters in postmenopausal women shows promising safety and efficacy data8.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Black, D. M., Thompson, A. R., Eastell, R. & Bouxsein, M. L. Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE. Lancet Diabetes Endocrinol. 12, 371–373 (2024).
Jensen, S. B. K. et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw. Open 7, e2416775 (2024).
Angitia Incorporated. Angitia Biopharmaceuticals presents first-in-human data on AGA2118 for osteoporosis at ASBMR 2024. GlobeNewswire News Room https://www.globenewswire.com/en/news-release/2024/09/30/2955094/0/en/Angitia-Biopharmaceuticals-Presents-First-in-Human-Data-on-AGA2118-for-Osteoporosis-at-ASBMR-2024.html (2024).
Babey, M. E. et al. A maternal brain hormone that builds bone. Nature 632, 357–365 (2024).
Li, N. et al. Schnurri-3 inhibition rescues skeletal fragility and vascular skeletal stem cell niche pathology in the OIM model of osteogenesis imperfecta. Bone Res. 12, 46 (2024).
Collins, J. M. et al. YAP and TAZ couple osteoblast precursor mobilization to angiogenesis and mechanoregulation in murine bone development. Dev. Cell 59, 211–227.e5 (2024).
Bandyopadhyay, S. et al. Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging. Cell 187, 3120–3140.e29 (2024).
Farr, J. N. et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat. Med. 23, 1072–1079 (2017).
Snyder, P. J. et al. Testosterone treatment and fractures in men with hypogonadism. N. Engl. J. Med. 390, 203–211 (2024).
Middelkoop, K. et al. Influence of vitamin D supplementation on bone mineral content, bone turnover markers, and fracture risk in South African schoolchildren: multicenter double-blind randomized placebo-controlled trial (ViDiKids). J. Bone Miner. Res. 39, 211–221 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Ambrosi, T.H. Surveying the landscape of emerging osteoanabolic therapies. Nat Rev Endocrinol 21, 75–76 (2025). https://doi.org/10.1038/s41574-024-01076-7
Published:
Issue date:
DOI: https://doi.org/10.1038/s41574-024-01076-7
